Navinci Diagnostics (formerly Olink Bioscience) develops and markets in situ proximity ligation assays for detecting proteins, their interactions, and post-translational modifications in tissue and cell samples. The company's initial focus is on immuno-oncology research and drug development. It is led by CEO Robert Gunnarsson. Navinci plans to soon launch the first commercially available assay to accurately detect PD‑1/PD‑L1 interactions in tissue samples. The company intends to use new funding to accelerate international commercialization and to form partnerships with pharma companies and firms with complementary technologies to offer complete solutions for customers. The recent Series A strengthens its position as it moves toward broader market entry.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2022